Clinical Associate Professor Lisa Horvath

Clinical Associate Professor, Staff Specialist Medical Oncologist
Medicine, Central Clinical School

C39 - Royal Prince Alfred Hospital
The University of Sydney
NSW 2006 Australia

T: +61 2 9515 7680
F: +61 2 9519 1546


2014 | 2013 | 2012 | 2011 | 2010 | 2009


  • Nagrial, A., Chang, D., Nguyen, N., Johns, A., Chantrill, L., Humphris, J., Chin, V., Samra, J., Gill, A., Pajic, M., Pinese, M., Colvin, E., Scarlett, C., Chou, A., Kench, J., Sutherland, R., Horvath, L., Biankin, A. (2014), Adjuvant chemotherapy in elderly patients with pancreatic cancer. British Journal of Cancer. 110(2), 313-319. [Abstract]
  • Yip, P., Cooper, W., Kohonen-Corish, M., Lin, B., McCaughan, B., Boyer, M., Kench, J., Horvath, L. (2014), Phosphorylated Akt expression is a prognostic marker in early-stage non-small cell lung cancer. Journal of Clinical Pathology. 67(4), 333-340. [Abstract]
  • Birch, S., Kench, J., Takano, E., Chan, P., Chan, A., Chiam, K., Veillard, A., Stricker, P., Haupt, S., Haupt, Y., Horvath, L., Fox, S. (2014), Expression of E6AP and PML predicts for prostate cancer progression and cancer specific death. Annals of Oncology. 25(12), 2392-2397. [Abstract]
  • Mahon, K., Qu, W., Devaney, J., Paul, C., Castillo, L., Wykes, R., Chatfield, M., Boyer, M., Stockler, M., Marx, G., Gurney, H., Mallesara, G., Molloy, P., Horvath, L., Clark, S. (2014), Methylated Glutathione S-transferase 1 (mGSTP1) is a potential plasma free DNA epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancer. British Journal of Cancer. 111(9), 1802-1809. [Abstract]
  • Sutherland, S., Pe Benito, R., Henshall, S., Horvath, L., Kench, J. (2014), Expression of phosphorylated-mTOR during the development of prostate cancer. The Prostate. 74(12), 1231-1239. [Abstract]
  • Lin, H., Castillo, L., Mahon, K., Chiam, K., Lee, B., Nguyen, Q., Boyer, M., Stockler, M., Pavlakis, N., Marx, G., Mallesara, G., Gurney, H., Clark, S., Swarbrick, A., Daly, R., Horvath, L. (2014), Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer. British Journal of Cancer. 110(10), 2462-2471. [Abstract]
  • Suttie, C., Hruby, G., Horvath, L., Thompson, J. (2014), Cardiac metastasis in merkel cell carcinoma. Journal of Clinical Oncology. 32(13), e52-53. [Abstract]


  • Selth, L., Townley, S., Bert, A., Stricker, P., Sutherland, P., Horvath, L., Goodall, G., Butler, L., Tilley, W. (2013), Circulating microRNAs predict biochemical recurrence in prostate cancer patients. British Journal of Cancer. 109(3), 641-650. [Abstract]
  • Hulf, T., Sibbritt, T., Wiklund, E., Patterson, K., Song, J., Stirzaker, C., Qu, W., Nair, S., Horvath, L., Armstrong, N., Kench, J., Sutherland, R., Clark, S. (2013), Epigenetic-induced repression of microRNA-205 is associated with MED1 activation and a poorer prognosis in localized prostate cancer. Oncogene. 32(23), 2891-2899. [Abstract]
  • Cooper, W., Yu, B., Yip, P., Ng, C., Lum, T., Farzin, M., Trent, R., Mercorella, B., Clarkson, A., Kohonen-Corish, M., Horvath, L., Kench, J., McCaughan, B., Gill, A., O'Toole, S. (2013), EGFR mutant-specific immunohistochemistry has high specificity and sensitivity for detecting targeted activating EGFR mutations in lung adenocarcinoma. Journal of Clinical Pathology. 66(9), 744-748. [Abstract]
  • Selinger, C., Rogers, T., Russell, P., O'Toole, S., Yip, P., Wright, G., Wainer, Z., Horvath, L., Boyer, M., McCaughan, B., Kohonen-Corish, M., Fox, S., Cooper, W., Solomon, B. (2013), Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization. Modern Pathology. 26(12), 1545-1553. [Abstract]
  • Yip, P., Yu, B., Cooper, W., Selinger, C., Ng, C., Kennedy, C., Kohonen-Corish, M., McCaughan, B., Trent, R., Boyer, M., Kench, J., Horvath, L., O'Toole, S. (2013), Patterns of DNA Mutations and ALK Rearrangement in Resected Node Negative Lung Adenocarcinoma. Journal of Thoracic Oncology. 8(4), 408-414. [Abstract]


  • Randall, S., McKay, M., Pascovici, D., Mahon, K., Horvath, L., Clarke, S., Molloy, M. (2012), Remarkable temporal stability of high-abundance human plasma proteins assessed by targeted mass spectrometry. Proteomics. Clinical Applications. 6(11-12), 626-634. [Abstract]
  • Goldstein, D., Spry, N., Cummins, M., Brown, C., van Hazel, G., Carroll, S., Selva-Nayagam, S., Borg, M., Ackland, S., Wratten, C., Shapiro, J., Porter, I., Hruby, G., Horvath, L., Bydder, S., Underhill, C., Harvey, J., Gebski, V. (2012), The GOFURTGO Study: AGITG Phase II Study of fixed dose rate gemcitabine-oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of localised pancreatic cancer. British Journal of Cancer. 106(1), 61-69. [Abstract]
  • Femia, G., Hardy, T., Spies, J., Horvath, L. (2012), Posterior reversible encephalopathy syndrome following chemotherapy with oxaliplatin and a fluoropyrimidine: a case report and literature review. Asia Pacific Journal of Clinical Oncology. 8(2), 115-122. [Abstract]
  • Savdie, R., Horvath, L., Benito, R., Rasiah, K., Haynes, A., Chatfield, M., Stricker, P., Turner, J., Delprado, W., Henshall, S., Sutherland, R., Kench, J. (2012), High Gleason grade carcinoma at a positive surgical margin predicts biochemical failure after radical prostatectomy and may guide adjuvant radiotherapy. BJU International. 109(12), 1794-1800. [Abstract]
  • Chua, W., Horvath, L., Beale, P., Clarke, S. (2012), Reporting clinical trial information: colorectal cancer trials at Sydney Cancer Centre. Internal Medicine Journal. 42(4), 416-421. [Abstract]
  • Venkateswaran, L., Butow, P., Jansen, J., Wilcken, N., Wong, M., Hui, R., Szonyi, G., Gebski, V., Naganathan, V., Horvath, L., Tattersall, M. (2012), Decision making in older patients with advanced cancer: does doctor know best?. Medical Journal of Australia. 196(1), 35-36. [Abstract]


  • Yip, P., Kench, J., Rasiah, K., Benito, R., Lee, C., Stricker, P., Henshall, S., Sutherland, R., Horvath, L. (2011), Low AZGP1 expression predicts for recurrence in margin-positive, localized prostate cancer. The Prostate. 71(15), 1638-45. [Abstract]
  • Kench, J., Clouston, D., Delprado, W., Eade, T., Ellis, D., Horvath, L., Samaratunga, H., Stahl, J., Stapleton, A., Egevad, L., Srigley, J., Delahunt, B. (2011), Prognostic factors in prostate cancer. Key elements in structured histopathology reporting of radical prostatectomy specimens. Pathology. 43(5), 410-9. [Abstract]
  • Mahon, K., Henshall, S., Sutherland, R., Horvath, L. (2011), Pathways of chemotherapy resistance in castration-resistant prostate cancer. Endocrine-Related Cancer. 18(4), R103-123. [Abstract]
  • Leighl, N., Shepherd, H., Butow, P., Clarke, S., McJannett, M., Beale, P., Wilcken, N., Moore, M., Chen, E., Goldstein, D., Horvath, L., Knox, J., Krzyzanowska, M., Oza, A., Feld, R., Hedley, D., Xu, W., Tattersall, M. (2011), Supporting Treatment Decision Making in Advanced Cancer: A Randomized Trial of a Decision Aid for Patients With Advanced Colorectal Cancer Considering Chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 29(15), 2077-84. [Abstract]
  • Cooper, W., O'toole, S., Boyer, M., Horvath, L., Mahar, A. (2011), What's new in non-small cell lung cancer for pathologists: the importance of accurate subtyping, EGFR mutations and ALK rearrangements. Pathology. 43(2), 103-115. [Abstract]
  • Devaney, J., Stirzaker, C., Qu, W., Song, J., Statham, A., Patterson, K., Horvath, L., Tabor, B., Coolen, M., Hulf, T., Kench, J., Henshall, S., Pe Benito, R., Haynes, A., Mayor, R., Peinado, M., Sutherland, R., Clark, S. (2011), Epigenetic deregulation across chromosome 2q14.2 differentiates normal from prostate cancer and provides a regional panel of novel DNA methylation cancer biomarkers. Cancer Epidemiology, Biomarkers & Prevention. 20(1), 148-159. [Abstract]


  • Ocean, A., Polite, B., Christos, P., Horvath, L., Hamilton, A., Matulich, D., Chen, H., Sparano, J., Kindler, H. (2010), Cetuximab is associated with excessive toxicity when combined with bevacizumab Plus mFOLFOX6 in metastatic colorectal carcinoma. Clinical Colorectal Cancer. 9(5), 290-296. [Abstract]
  • Bianco-Miotto, T., Chiam, K., Buchanan, G., Jindal, S., Day, T., Thomas, M., Pickering, M., O'Loughlin, M., Ryan, N., Raymond, W., Horvath, L., Kench, J., Stricker, P., Marshall, V., Sutherland, R., Henshall, S., Gerald, W., Scher, H., Risbridger, G., Clements, J., Butler, L., Tilley, W., Horsfall, D., Ricciardelli, C. (2010), Global Levels of Specific Histone Modifications and an Epigenetic Gene Signature Predict Prostate Cancer Progression and Development. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 19(10), 2611-22. [Abstract]
  • Thanigasalam, R., Rasiah, K., Stricker, P., Haynes, A., Sutherland, S., Sutherland, R., Henshall, S., Horvath, L. (2010), Stage migration in localized prostate cancer has no effect on the post-radical prostatectomy Kattan nomogram. BJU international. 105(5), 642-7. [Abstract]


  • Karim, R., Gerega, S., Yang, Y., Horvath, L., Spillane, A., Carmalt, H., Scolyer, R., Lee, C. (2009), Proteins from the Wnt pathway are involved in the pathogenesis and progression of mammary phyllodes tumours. Journal of Clinical Pathology. 62(11), 1016-1020. [Abstract]
  • Zhao, L., Lee, B., Brown, D., Molloy, M., Marx, G., Pavlakis, N., Boyer, M., Stockler, M., Kaplan, W., Breit, S., Sutherland, R., Henshall, S., Horvath, L. (2009), Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling. Cancer Research. 69(19), 7696-7703. [Abstract]
  • Tattersall, M., Dear, R., Jansen, J., Shepherd, H., J Devine, R., G Horvath, L., Boyer, M. (2009), Second opinions in oncology: the experiences of patients attending the Sydney Cancer Centre. Medical Journal of Australia. 191(4), 209-212. [Abstract]
  • Balanathan, P., Williams, E., Wang, H., Pedersen, J., Horvath, L., Achen, M., Stacker, S., Risbridger, G. (2009), Elevated level of inhibin-alpha subunit is pro-tumourigenic and pro-metastatic and associated with extracapsular spread in advanced prostate cancer. British Journal of Cancer. 100(11), 1784-1793. [Abstract]